Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Lianbo Yu, PhD"'
Autor:
Hui-Zi Chen, MD, PhD, Russell Bonneville, BS, Anoosha Paruchuri, PhD, Julie W. Reeser, PhD, Michele R. Wing, PhD, Eric Samorodnitsky, PhD, Melanie A. Krook, PhD, Amy M. Smith, BS, Thuy Dao, BS, Jharna Miya, MS, Walter Wang, BS, Lianbo Yu, PhD, Aharon G. Freud, MD, PhD, Patricia Allenby, MD, Sharon Cole, MD, Gregory Otterson, MD, Peter Shields, MD, David P. Carbone, MD, PhD, Sameek Roychowdhury, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 4, Pp 100164- (2021)
Introduction: Relapsed SCLC is characterized by therapeutic resistance and high mortality rate. Despite decades of research, mechanisms responsible for therapeutic resistance have remained elusive owing to limited tissues available for molecular stud
Externí odkaz:
https://doaj.org/article/d41ee449b2bc4d2ab3b5a1f76d7484c9
Autor:
Dionisia Quiroga DO, PhD, Robert Wesolowski MD, Sara Zelinskas BS, Ashley Pinette MD, Brooke Benner PhD, Emily Schwarz BS, Himanshu Savardekar BS, Courtney Johnson DO, Andrew Stiff MD, PhD, Lianbo Yu PhD, Erin Macrae MD, Maryam Lustberg MD, MPH, Ewa Mrozek MD, Bhuvaneswari Ramaswamy MD, William E. Carson MD
Publikováno v:
Cancer Control, Vol 31 (2024)
Objectives CpG ODN is a Toll-like receptor 9 agonist with immunotherapeutic potential for many cancer types, including aggressive breast cancers. There is strong interest in utilizing CpG ODN as an adjuvant to improve clinical efficacy of current tre
Externí odkaz:
https://doaj.org/article/c4a04ac8a9714a0fa31cf6f588fbd325